The most useful oil in the world is also one of the most destructive. Palm oil is in half the products on a supermarket shelf, from shampoo to ice cream, because it is cheap, stable, and functionally hard to beat. Its production is also a primary driver of tropical deforestation, responsible for millions of tons of annual carbon emissions. For consumer brands, it is an ESG headache baked into the supply chain.
C16 Biosciences, a New York biotech startup, thinks the answer is not a different crop, but a different process. Using a proprietary strain of yeast, the company ferments sugar to produce oils that mimic the performance of palm oil, without the plantations. They call the platform Palmless™. The bet is that for beauty and food companies staring down Scope 3 emissions targets, a drop-in, deforestation-free alternative will be worth the premium.
A fermentation wedge into a $61B market
The company’s strategic wedge is straightforward: replace a problematic commodity with a precision-brewed one. Palm oil is a $61 billion global industry [C16 Biosciences], and its supply chain is notoriously opaque and linked to land-use change. C16’s alternative is produced in a controlled fermentation tank, offering brands a claim of traceability and carbon reduction alongside functional parity.
Their first commercial beachhead is the beauty and personal care sector, where they launched Torula Oil in 2023 [SPEEDA Edge, Jan 2024]. The logic is sound. Beauty brands often command higher margins and face intense consumer pressure on sustainability, making them early adopters for a novel, premium ingredient. The company says its Palmless™ ingredients are now trusted by leading brands in beauty, home care, and food [gopalmless.com, 2026].
Scaling from lab to industrial tank
Biotech dreams often falter at the scale-up phase. C16’s most tangible proof point is a 50,000-liter industrial fermentation run, which it has successfully executed [SPEEDA Edge, Jan 2024]. This is not lab-scale tinkering; it’s a demonstration of commercial-grade production. The company operates from a 20,000-square-foot facility in Midtown Manhattan, an unusual location for a fermentation business that speaks to its urban, biotech-focused origins [SPEEDA Edge, Jan 2024].
The company’s funding history shows investors betting on that technical de-risking. A $20 million Series A in 2020 was led by Breakthrough Energy Ventures, Bill Gates’s climate fund [SPEEDA Edge, Jan 2024]. More recently, a $3.5 million grant from the Bill & Melinda Gates Foundation in early 2024 signals continued non-dilutive support for the platform’s development [Crunchbase, 2024]. In total, the company has raised approximately $30 million [PitchBook, 2024].
| Round | Date | Amount (USD) | Lead Investor |
|---|---|---|---|
| Series A | March 2020 | $20,000,000 | Breakthrough Energy Ventures [SPEEDA Edge, Jan 2024] |
| Grant | January 2024 | $3,500,000 | Bill & Melinda Gates Foundation [Crunchbase, 2024] |
| Venture | October 2023 | $1,000,000 | Elemental Excelerator [SPEEDA Edge, Jan 2024] |
The team and the long game in food
The founding trio,Shara Ticku (CEO), Harry McNamara, and David Heller (COO),met while studying at MIT and Harvard [Breakthrough Energy]. They have steered the company through Y Combinator and built a team of around 35 employees based in New York [Y Combinator]. The scientific leadership, with McNamara as Chief Science Officer, is focused on the platform’s expansion beyond beauty.
The next, and far larger, frontier is food. Palm oil is ubiquitous in packaged foods for its texture and shelf stability. C16 is actively working toward FDA GRAS (Generally Recognized As Safe) status for its oils in edible products [zoonop.com, 2026]. This regulatory milestone is a critical gate. Without it, the addressable market is limited to topical applications. With it, the company can take aim at the core of the $61 billion industry.
Where the economics get sticky
The ambition is clear, but the path is lined with formidable challenges. The unit economics of precision fermentation must eventually compete with one of the world’s most efficiently produced agricultural commodities. Palm oil is cheap. Very cheap. The cost to produce a metric ton of crude palm oil can be well under $500. Fermentation-based oils, for all their environmental advantages, start at a significant cost disadvantage.
C16 is not alone in the race. The field is getting crowded, and the winner will likely be the one that achieves the highest yield and lowest production cost at scale.
- The price premium. For brands, the calculus is not just cost-per-ton but total cost of compliance. A Palmless™ ingredient must be priced at a point where a brand’s sustainability team can justify the premium to the procurement office. The value is in risk reduction and marketing claims, which are real but harder to quantify than a line item.
- The scale mountain. A 50,000-liter run is impressive, but global palm oil production is measured in hundreds of millions of tons annually. Building fermentation capacity at that scale represents a capital expenditure challenge orders of magnitude greater than what $30 million can address.
- The regulatory clock. FDA review is not a swift process. While the beauty sector provides revenue and validation, the food approval timeline is a variable outside the company’s control that could delay its largest market opportunity.
The company’s most plausible answer is that it doesn’t need to replace all palm oil tomorrow. It needs to serve the growing segment of brands for whom “deforestation-free” is a non-negotiable supply chain requirement, and who will pay for it. From that beachhead, iterative gains in yield and process efficiency can slowly widen the economic wedge.
The next twelve months
For C16, the immediate milestones are concrete. Securing that FDA GRAS designation is paramount. Concurrently, the company will need to demonstrate it can move from successful pilot runs to consistent, cost-effective production that can supply multiple large brands. Another funding round, likely a Series B, seems a logical step in the next year to finance the capital-intensive build-out of production capacity.
On the back of an envelope, the math is a stark reminder of the challenge. If C16’s entire current raised capital of $30 million were spent solely on production, and assuming a wholesale price ten times that of conventional palm oil, it might cover the cost of a few thousand tons of product. The global market consumes over 70 million tons annually. The company’s real task is to use its capital to prove the unit economics can work at scale, convincing a strategic partner or a later-stage investor to fund the billion-dollar infrastructure required.
C16 Biosciences is not trying to out-farm the palm plantations of Indonesia. It is trying to out-engineer them. The incumbent it must beat is not a company, but an entire agricultural system optimized for low cost over decades. For now, the bet is that a tank in Manhattan, filled with hungry yeast, can brew a more sustainable future, one liter at a time.
Sources
- [SPEEDA Edge, Jan 2024] C16 Biosciences company profile | https://www.c16bio.com/
- [Crunchbase, 2024] C16 Biosciences funding details | https://www.crunchbase.com/organization/c16-biosciences
- [PitchBook, 2024] C16 Biosciences financials | https://pitchbook.com/profiles/company/232078-96
- [C16 Biosciences] Company mission and market sizing | https://www.c16bio.com/
- [gopalmless.com, 2026] Palmless brand and customer claims | https://gopalmless.com/
- [zoonop.com, 2026] Information on FDA GRAS status pursuit | https://zoonop.com/
- [Breakthrough Energy] C16 Biosciences team overview | https://www.breakthroughenergy.org/
- [Y Combinator] C16 Biosciences YC profile | https://www.ycombinator.com/companies/c16-biosciences